Annual report for Glenmark Pharmaceuticals Ltd. for FY-2014
08-05-2014
Glenmarks novel monoclonal antibody GBR 900 for treatment of chronic pain entering human trials
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated April 29, 2014 titled "Glenmarks novel monoclonal antibody GBR 900 for treatment of chronic pain entering human trials".29-04-2014
FY14 results on May 08, 2014
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 08, 2014:1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2014.2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2014....28-04-2014